1832 Asset Management
JUNO

1832 Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

1832 Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-70,900
Closed -$3.23M – 771
2017
Q4 		$3.23M Buy
70,900
+50,300
+244% +$2.51M 0.01% 327
2017
Q3 		$896K Buy
+20,600
New +$702K ﹤0.01% 432
2016
Q3 		– Sell
-95,200
Closed -$3.6M – 782
2016
Q2 		$3.6M Buy
+95,200
New +$3.95M 0.01% 325

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

1832 Asset Management's JUNO Position: Q1 2018 in Review

1832 Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 70,900 shares — an estimated $3.23M sold.

1832 Asset Management first reported a position in JUNO in Q2 2016 and held it in 3 quarters. The position peaked at $3.6M in Q2 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • 1832 Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • 1832 Asset Management sold 70,900 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.23M.
  • 1832 Asset Management first reported a position in Juno Therapeutics, Inc. in Q2 2016 and held it in 3 quarters.
  • 1832 Asset Management's Juno Therapeutics, Inc. position peaked at $3.6M in Q2 2016.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on 1832 Asset Management's 13F filing for Q1 2018, filed 15 May 2018.